CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 380 enrolled
Drug / intervention
Infliximabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00988832
NCT00988832N/ACompleted

A UK Retrospective Audit of Patients With Crohn's Disease Treated With Infliximab

Merck Sharp & Dohme LLC·observational·Posted Oct 2, 2009·Updated Sep 2, 2015

In Brief

An observational study evaluating Infliximab for Crohn's Disease. Completed, enrolled 380 participants.

Detailed Summary

The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs associated with the treatment of Crohn's Disease.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2009
Enrollment StartFeb 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.8 years ago

Interventions

Infliximabbiological

Infliximab as prescribed by a physician in normal practice for Crohn's disease